Retaspimycin

Star0

DB05626InvestigationalSmall molecule

Investigated for use/treatment in gastric cancer, lung cancer, and multiple myeloma.

Mechanism: Pharmacologically active on Heat shock protein HSP 90-alpha and Heat shock protein HSP 90-beta
Curator reviewed
Primary indication: Investigated for use/treatment in gastric cancer, lung cancer, and multiple myeloma.Curator reviewed
Formula / weight: C₃₁H₄₅N₃O₈ · 587.714 g/mol (avg)
Code names: IPI-504

Resolves to

Compound

UNIIBZF2ZM0I5ZCAS857402-23-4ChEMBLCHEMBL1184904ChEBI71975

Structure

InChIKeyOAKGNIRUXAZDQF-TXHRRWQRSA-NSMILESCO[C@H]1C[C@H](C)CC2=C(NCC=C)C(O)=CC(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)=C2O

Targets

P07900HSP90AA1P08238HSP90AB1

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Retaspimycin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account